Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis.
Guler S, Sarbu AC, Stalder O, Allanore Y, Bernardino V, Distler J, Gabrielli A, Hoffmann-Vold AM, Matucci-Cerinic M, Müller-Ladner U, Ortiz-Santamaria V, Rednic S, Riccieri V, Smith V, Ullman S, Walker UA, Geiser TK, Distler O, Maurer B, Kollert F. Guler S, et al. Thorax. 2023 Dec;78(12):1188-1196. doi: 10.1136/thorax-2023-220541. Epub 2023 Oct 5. Thorax. 2023. PMID: 37798114
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort.
Hughes M, Huang S, Alegre-Sancho JJ, Carreira PE, Engelhart M, Hachulla E, Henes J, Kerzberg E, Pozzi MR, Riemekasten G, Smith V, Szücs G, Vanthuyne M, Zanatta E, Distler O, Gabrielli AG, Hoffmann-Vold AM, Steen VD, Khanna D; EUSTAR Collaborators. Hughes M, et al. Rheumatology (Oxford). 2023 Feb 6;62(SI):SI54-SI63. doi: 10.1093/rheumatology/keac363. Rheumatology (Oxford). 2023. PMID: 35731139
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
Hoffmann-Vold AM, Brunborg C, Airò P, Ananyeva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Valentini G, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR collaborators. Hoffmann-Vold AM, et al. Chest. 2023 Mar;163(3):586-598. doi: 10.1016/j.chest.2022.09.044. Epub 2022 Oct 14. Chest. 2023. PMID: 36244404
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, Damjanov N, Rednic S, Ribi C, Bancel DF, Hoffmann-Vold AM, Gabrielli A, Distler O, Khanna D, Allanore Y; EUSTAR collaborators. Lescoat A, et al. JAMA Dermatol. 2023 Aug 1;159(8):837-847. doi: 10.1001/jamadermatol.2023.1729. JAMA Dermatol. 2023. PMID: 37378994 Free PMC article.
Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort.
Colalillo A, Pellicano C, Ananyeva LP, Hachulla E, Cuomo G, Györfi AH, Czirják L, de Vries-Bouwstra J, Mouthon L, Poormoghim H, Del Galdo F, Hunzelmann N, Spierings J, Kuwana M, Rosato E; and the EUSTAR Collaborators. Colalillo A, et al. Arthritis Care Res (Hoboken). 2023 Jul 17. doi: 10.1002/acr.25196. Online ahead of print. Arthritis Care Res (Hoboken). 2023. PMID: 37458105 Free article.
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
Kreuter M, Bonella F, Blank N, Riemekasten G, Müller-Ladner U, Henes J, Siegert E, Günther C, Kötter I, Pfeiffer C, Schmalzing M, Zeidler G, Korsten P, Susok L, Juche A, Worm M, Jandova I, Ehrchen J, Sunderkötter C, Keyßer G, Ramming A, Schmeiser T, Kreuter A, Kuhr K, Lorenz HM, Moinzadeh P, Hunzelmann N. Kreuter M, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3067-3074. doi: 10.1093/rheumatology/kead023. Rheumatology (Oxford). 2023. PMID: 36708008 Free PMC article.
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P, Bonella F, Oberste M, Weliwitage J, Blank N, Riemekasten G, Müller-Ladner U, Henes J, Siegert E, Günther C, Kötter I, Pfeiffer C, Schmalzing M, Zeidler G, Korsten P, Susok L, Juche A, Worm M, Jandova I, Ehrchen J, Sunderkötter C, Keyßer G, Ramming A, Schmeiser T, Kreuter A, Lorenz HM, Hunzelmann N, Kreuter M. Moinzadeh P, et al. Chest. 2024 Jan;165(1):132-145. doi: 10.1016/j.chest.2023.08.013. Epub 2023 Aug 13. Chest. 2024. PMID: 37582424 Free article.
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators. Hasseli R, et al. RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998. RMD Open. 2023. PMID: 37068915 Free PMC article.
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework.
Della-Torre E, Talarico R, Ballarin J, Bozzalla-Cassione E, Cardamone C, Cigolini C, Ferro F, Fonseca T, Fragoulis GE, Galetti I, Gerosa M, Hernández-Rodríguez J, Lanzillotta M, Marinello D, Martin T, Martinez-Valle F, Maślińska M, Moretti M, Mosca M, Müller-Ladner U, Nalli C, Orsolini G, Pamfil C, Perez-Garcia G, Priori R, Quattrocchio G, Ramming A, Regola F, Romão VC, Silva A, van Laar JAM, Vicente-Edo MJ, Vinker S, Alexander T. Della-Torre E, et al. Among authors: muller ladner u. Lancet Rheumatol. 2024 Oct 29:S2665-9913(24)00192-9. doi: 10.1016/S2665-9913(24)00192-9. Online ahead of print. Lancet Rheumatol. 2024. PMID: 39486422 Review.
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries.
Hasseli R, Hanses F, Stecher M, Specker C, Weise T, Borgmann S, Hasselberger M, Hertenstein B, Hower M, Hoyer BF, Koll C, Krause A, von Lilienfeld-Toal M, Lorenz HM, Merle U, Nunes de Miranda SM, Pletz MW, Regierer AC, Richter JG, Rieg S, Roemmele C, Ruethrich MM, Schmeiser T, Schulze-Koops H, Strangfeld A, Vehreschild MJGT, Voit F, Voll RE, Vehreschild JJ, Müller-Ladner U, Pfeil A. Hasseli R, et al. Front Med (Lausanne). 2024 Mar 6;11:1332716. doi: 10.3389/fmed.2024.1332716. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38510457 Free PMC article.
648 results